Cardiff Oncology (CRDF) announced that the United States Patent and Trademark Office has issued to Cardiff Oncology U.S. patent No. 12,263,173 with an expected expiration date of no earlier than 2043. The claims of the patent cover the method of using onvansertib in combination with bevacizumab in any line of therapy for the treatment of metastatic colorectal cancer patients who have not previously been treated with bev. Cardiff Oncology announced initial data from the ongoing CRDF-004 trial in December, 2024. Additional clinical data from the trial is expected in 1H of 2025.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Cardiff Oncology completes patient enrollment in CRDF-004 trial
- Cardiff Oncology initiated with a Buy at Lucid Capital
- Cardiff Oncology’s Earnings Call: Optimism Amid Challenges
- Cardiff Oncology price target raised to $17 from $13 at H.C. Wainwright
- Cardiff Oncology Highlights Progress in Cancer Trials